Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I RSVt intranasal vaccine in Japanese toddlers
jRCT2051230020Phase 1Completed
- Sponsor
- Sanofi
- Start
- May 2023
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in respiratory syncytial virus disease (RSV) comparing RSVt intranasal vaccine with Placebo intranasal (2 arms). Primary endpoints: Immediate unsolicited systemic adverse events within 30 minutes, Solicited administration site and systemic reactions and 4 more. Started May 2023; status: completed.
02
Drugs
SP0125
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2051230020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230020.